Denosumab for the treatment of osteoporosis: A systematic literature review

Silva-Fernández, Lucía; Rosario, María Piedad; Martínez-López, Juan Antonio; Carmona, Loreto; Loza, Estíbaliz

doi:10.1016/j.reuma.2012.06.007

Cited by 38 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Denosumab has been used with excellent results in the treatment of osteoporosis, skeletal metastases, and GCTs [8,15,18]. Concerns about patient safety with denosumab have also been answered by studies evaluating its side effects [17].…”

Section: Discussionmentioning

confidence: 99%

“…Concerns about patient safety with denosumab have also been answered by studies evaluating its side effects [17]. An increased risk of urinary infections and eczema, and rare adverse events involving serious infection and osteonecrosis of the jaw, have been reported in patients receiving denosumab therapy for osteoporosis [11,15]. Beyond that, the therapeutic use of denosumab appears to be safe, but there is clearly a need for further studies to assess potential side effects when denosumab is used to treat pediatric patients and to investigate the appropriate duration of therapy.…”

Section: Discussionmentioning

confidence: 99%

“…RANKL inhibition blocks osteoclast maturation and function [16], and denosumab has been successfully used in the treatment of osteoporosis [15] and skeletal metastases [8], and more recently in GCT therapy as well [18]. The satisfactory results with denosumab in the treatment of GCTs and the clear immunohistochemical similarity and relationship between GCTs and ABCs [19] justify the hypothesis that denosumab may also have positive effects on ABCs.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts

et al. 2013

View full text Add to dashboard Cite

Introduction Aneurysmal bone cysts (ABCs) are expansive and destructive lesions positive for osteoclast markers, resembling benign giant cell tumors (GCTs). Treatment options include surgical resection, curettage and cavity filling, embolization, injection of fibrosing agents, or radiotherapy. Particularly in children and adolescents with spinal ABCs, these options may be unsatisfactory, and innovative forms of treatment are needed. Denosumab is a human monoclonal antibody that inhibits osteoclast function by blocking the cytokine receptor activator of the nuclear factor-kappa B ligand. Satisfactory results with denosumab in treating GCTs and immunohistochemical similarities suggest that it may also have positive effects on ABCs. Methods and ResultsThis report is the first description of the therapeutic use of denosumab in two patients with spinal ABCs. Two boys (aged 8 and 11) had recurrent ABCs at C5 after surgery with intralesional tumor resection. Treatment options were discussed by the interdisciplinary tumor board. Arterial embolization was attempted, but failed due to an absence of appropriate afferent arteries. After the families had received extensive information and provided written consent, denosumab therapy was initiated as an individualized treatment, despite the absence as yet of scientific evidence. After the start of denosumab therapy, both patients recovered from pain and neurologic symptoms significantly and are now in a healthy condition with no severe side effects. Magnetic resonance imaging check-ups after 2 or 4 months of denosumab treatment, respectively, showed tumor regression in both patients. Discussion Longer follow-up and clinical studies are warranted to establish the value of denosumab in the treatment of ABCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Current treatment strategies for osteoporosis, such as bisphosphates or an antibody targeting RANKL 136 , ameliorate disease by inhibiting the breakdown of bone through targeting the osteoclasts. Preclinical development is underway for antibodies targeting Siglec-15.…”

mentioning

confidence: 99%

Siglec-mediated regulation of immune cell function in disease

2014

View full text Add to dashboard Cite

All mammalian cells display a diverse array of glycan structures that differ from those found on microbial pathogens. Siglecs are a family of sialic acid-binding immunoglobulin-like receptors that participate in the discrimination of ‘self’ and ‘non-self’ and regulate the functions of cells in the innate and adaptive immune systems through recognition of their glycan ligands. In this review, we describe the recent advances in our understanding of the roles of Siglecs in the regulation of immune cell functions in infectious diseases, inflammation, neurodegeneration, autoimmune diseases and cancer.

show abstract

“…If administration of denosumab is withdrawn, inhibition of RANKL and suppression of osteoclast activity are reversed immediately, which results in the consecutive loss of BMD [52]. Denosumab decreased the risk for osteoporotic fractures sufficiently and is therefore an effective alternative for the prevention and treatment of AIBL in postmenopausal women [53]. …”

Section: Therapy With Bisphosphonates and Denosumab To Prevent Aiblmentioning

confidence: 99%

Breast Cancer and Osteoporosis - Management of Cancer Treatment-Induced Bone Loss in Postmenopausal Women with Breast Cancer

Kalder

Hadji

2014

Breast Care

View full text Add to dashboard Cite

The incidence of breast cancer (BC) in postmenopausal women is continuously rising. Due to early diagnosis and various treatment designs, the long-term clinical outcome has improved. Frequent settings are chemotherapy as well as endocrine treatment. Both have proven to interfere with bone health resulting in cancer treatment-induced bone loss (CTIBL). Whereas chemotherapy is associated with increased bone resorption, aromatase inhibitor (AI) therapy reduces residual estrogen and is associated with decreased bone mineral density. Independent of the AI administered, the loss of bone mineral density is twice as high compared to healthy postmenopausal women. As a consequence of CTIBL, both chemotherapy and AI treatment can lead to a significantly increased fracture risk. Therefore, several guidelines have emerged for the management of CTIBL in women with BC, including strategies to identify and treat those at high risk for fractures. Further research on tracking guideline adherence examining the feasibility and practicability of guideline implementation to bridge the gap between determined scientific best evidence and applied best practice is needed to adjust these guidelines in the future.

show abstract

Denosumab for the treatment of osteoporosis: A systematic literature review

Cited by 38 publications

References 37 publications

Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts

Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts

Siglec-mediated regulation of immune cell function in disease

Breast Cancer and Osteoporosis - Management of Cancer Treatment-Induced Bone Loss in Postmenopausal Women with Breast Cancer

Contact Info

Product

Resources

About